Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Acute myeloid (myelogenous, nonlymphocytic) leukemia in adults; hormone-refractory prostate cancer. (In combination with other chemotherapeutic agents) Clinical selection for Mitozantrone should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
IV 100-120mg/m2, given on Day 1 of cycle or divided into 2 doses and given on Day 1 and Day 8. It is repeated every 2128 days for 6 cycles [in combination with other chemotherapy agents]. Consult specialist literature for further information.
Myelosuppression; cardiac toxicity and congestive heart failure; triad of back pain; flushing; and chest tightness; increased appetite; dysphagia; GI haemorrhage; gastritis; stomatitis; nausea and vomiting; gingival bleeding; hemorrhoids; melena; diarrhea; abdominal pain; anorexia; and constipation; dry mouth; taste perversion; thirst; hiccups; or tooth caries; neuropathy; amnesia; anxiety; ataxia; confusion; emotional lability; hallucination; hyperkinesias; hypertonia; tremor; somnolence; seizures; alopecia; pigmentation of fingernails and toenails; severe local tissue dam-age in extravasation; fever; myalgia; hypocalcaemia; hypersensitivity reactions; colouring of urine blue-green for 24 hours after administration.
Store as labelled. Keep out of reach of children.